BACKGROUND: Varying strategies are currently being evaluated to develop tissue-engineered constructs for the treatment of ischemic heart disease. This study examines an angiogenic and biodegradable cardiac construct seeded with neonatal cardiomyocytes for the treatment of chronic heart failure (CHF). METHODS: We evaluated a neonatal cardiomyocyte (NCM)-seeded 3-dimensional fibroblast construct (3DFC) in vitro for the presence of functional gap junctions and the potential of the NCM-3DFC to restore left ventricular (LV) function in an in vivo rat model of CHF at 3 weeks after permanent left coronary artery ligation. RESULTS: The NCM-3DFC demonstrated extensive cell-to-cell connectivity after dye injection. At 5 days in culture, the patch contracted spontaneously in a rhythmic and directional fashion at 43 Ϯ 3 beats/min, with a mean displacement of 1.3 Ϯ 0.3 mm and contraction velocity of 0.8 Ϯ 0.2 mm/sec. The seeded patch could be electrically paced at nearly physiologic rates (270 Ϯ 30 beats/min) while maintaining coordinated, directional contractions. Three weeks after implantation, the NCM-3DFC improved LV function by increasing (p o 0.05) ejection fraction 26%, cardiac index 33%, dP/dt(þ) 25%, dP/dt(-) 23%, and peak developed pressure 30%, while decreasing (p o 0.05) LV end diastolic pressure 38% and the time constant of relaxation (Tau) 16%. At 18 weeks after implantation, the NCM-3DFC improved LV function by increasing (p o 0.05) ejection fraction 54%, mean arterial pressure 20%, dP/dt(þ) 16%, dP/dt(-) 34%, and peak developed pressure 39%. CONCLUSIONS: This study demonstrates that a multicellular, electromechanically organized cardiomyocyte scaffold, constructed in vitro by seeding NCM onto 3DFC, can improve LV function long-term when implanted in rats with CHF.
cardiac function. Recently, a number of novel strategies have been proposed for improving functional and clinical outcomes of patients with CHF such as, cell-based therapies, 1 in vivo tissue reprogramming, 2 and gene therapy. 3 Each of these approaches may carry therapeutic potential, but cell-based therapies offer the least cumbersome approach and are not complicated by in vivo viral or gene administration.
Evaluation of cell-based therapies for CHF has progressed through a number of clinical trials. [4] [5] [6] [7] [8] [9] [10] Although questions remain regarding the most effective cell type and dosing strategies, the major limitation to success may be the development of an effective cell-delivery system. Current delivery techniques, for the most part, use direct injection by catheter-based systems that result in limited cellular survival and minimal retention of cells in the target area. 11, 12 As a result, new cell-delivery strategies, such as tissue engineered constructs, are being developed that provide structural support facilitating implanted cell survival and integration into the underlying myocardium. [13] [14] [15] Previous studies by our laboratory, and others, have tested a 3-dimensional fibroblast construct (3DFC) consisting of viable human dermal fibroblasts embedded onto a bioabsorbable polymeric Vicryl mesh (Ethicon, Somerville, NJ) that does not elicit an immunologic response. [16] [17] [18] Implantation of this 3DFC immediately after myocardial infarction (MI) or in an ischemic CHF model, 3 weeks after permanent occlusion of the left coronary artery, results in formation of a microvascular bed and the consequent increase in myocardial blood flow to the infarcted tissue. 19, 20 The embedded fibroblasts are an important component of the bioengineered scaffold because dermal fibroblasts have been demonstrated to play a role in microvascular organization in vitro through paracrine-mediated effects or other factors. [21] [22] [23] Yet, implanting the 3DFC alone in CHF did not improve cardiac function. 19, 20 In the present study, we explored the potential of the microvascular bed induced by the 3DFC to support an overlaying population of cardiomyocytes seeded on the 3DFC. We demonstrate that rat neonatal cardiomyocytes (NCM) can be successfully cocultured with human fibroblasts in a biodegradable scaffold and that they form an electromechanically organized syncytium capable of improving the left ventricular (LV) function of a chronically infarcted heart.
Methods

The 3DFC
The 3DFC is a cryopreserved bioabsorbable scaffold populated with human neonatal fibroblasts. 16, 17 The fibroblasts have been tested for cell morphology, karology, isoenzymes, and tumorigenicity and are free from viruses, retroviruses, endotoxins, and mycoplasma. The 3DFC was provided by Theregen Inc (San Francisco, CA) frozen (-751 Ϯ 101C) in 5 Â 7.5 cm pieces with an average thickness of 200 μm. The 3DFC is thawed in phosphate buffered saline (341C-371C) and handled gently to limit cellular damage. The 3DFC does not generate an immune response [16] [17] [18] [19] [20] (investigators' brochure ITT-101, Theregen).
Cardiomyocyte isolation, seeding, and culture
Cardiomyocytes were isolated from 1-to 2-day-old neonatal Sprague-Dawley (Harlan, Indianapolis, IN) rat hearts. Briefly, the hearts were excised, the atria were removed, and the ventricles were minced into 0.5-to 1-mm portions and digested in a pancreatin/collagenase solution. After each enzymatic digest, cardiomyocytes were collected, combined, and resuspended in Dulbecco Modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS). Lastly, the suspension was differentially plated in Ham's F-12 with 100 mg/ml bovine serum albumin.
The 3DFC was thawed, cut into 1.5-cm diameter sections, and seeded with NCM at densities ranging from 0.6 Â 10 6 to 2.7 Â 10 6 cells/cm 2 using methods developed in our laboratory. The NCM and NCM-3DFC were cultured in 10% FBS in DMEM-LG (GibcoInvitrogen, Carlsbad, CA), maintained at 371C and 5% CO 2 . Patches were constructed as described for in vitro and in vivo evaluation. The NCM-3DFC patches for in vivo evaluation were seeded, cultured, and implanted onto the rat heart 3 weeks after left coronary artery ligation within 18 hours of seeding. Patches prepared for in vitro evaluation were seeded and cultured 1 to 10 days.
Quantitative measurements of cardiomyocytes and fibroblasts
Serial stained tissue samples were reacted with specific markers for cardiomyocytes (troponin) and fibroblasts (vimentin). Immunohistochemically reacted glass slides were digitally scanned (wholeslide scanning) using an Aperio scanner (Aperio, Vista, CA), with subsequent FACTS (Feature Analysis on Consecutive Tissue Sections). Whole-slide scanning allowed for an objective digital quantitative analysis of the entire tissue sections to ensure against investigator bias. The parameters for a generic image analysis algorithm for quantifying cells were independently adjusted for counting cardiomyocytes and fibroblasts. This was used for the objective analysis. The algorithm-based FACTS process performs image-to-image registration on prepared tissue sections on each glass slide. The FACTS process was used to align the serial sections to ensure that corresponding areas were analyzed in each stained slide to provide a fair sample comparison.
Field stimulation and pacing
NCM-seeded 3DFC patches were transferred to a thermoregulated culture well (Bipolar Temperature Controller; Medical Systems, Greenvale, NY) containing culture medium maintained at 371C. The NCM-3DFC were paced (S44; Grass Instruments, Quincy, MA) by field stimulation ($7 V) through 99.7% pure silver wires placed into the culture well on opposing sides of the NCM-3DFC. The pacing rate varied from 60 to 270 Ϯ 30 beats/min for 10 seconds.
Cell-to-cell communication ; mol wt 280, net charge 1þ, 10 mmol/liter), Alexa 350 (mol wt 326, net charge 1-, 10 mmol/liter), and rhodamine dextran (0.1 mg/ml; both Molecular Probes; Invitrogen, Carlsbad, CA).
Microelectrode tips were created from 1.0-mm filament glass (A-M Systems, Sequim, WA) on a Sutter Instruments puller (Novato, CA), their tips filled by capillary action with the dye mixture and backfilled with 3 mol/liter KCl. The microelectrodes were lowered onto a cell field in the preparation until contact with a cell surface was achieved and cytoplasm access was gained. The dyes were slowly and continuously injected by a slight capacitance overcompensation of the amplifier (SEC-05LX; NPI Electronics, Tamm, Germany). Images were captured at different times during the next 5 to 20 minutes. Halothane, a known gap junction inhibitor, was added to the superfusate (final concentration, $8 mmol/liter) to temporarily decrease intercellular dye diffusion and further confirm the transjunctional nature of this phenomenon. [25] [26] [27] Multielectrode array electrical mapping
The NCM-3DFC was electrophysiologically mapped in real-time using a 10-electrode custom-designed multielectrode array (Ad-Tech Medical Instrument Corp, Racine, WI) and a 1-kHz low-pass filter. Action potentials were collected using a BIOPAC MP150 (BIOPAC Systems Inc, Goleta, CA) data acquisition system with MCE100C signal conditioning modules. The MCE module has multiple gain settings from 10 to 1,000 and an onboard configurable signal filter. Up to 16 channels of data were acquired simultaneously at a 5-kHz sampling rate. Notch filters were configured in the data acquisition system for removing the 60 Hz noise and its higher harmonics. Data recordings were collected in 10-second intervals. Seeded patches were evaluated in vitro at 1 to 8 days in culture for spontaneous field potential amplitude, duration, conduction velocities, propagation patterns, and monophasic action potentials. The NCM-3DFC was maintained at 371C in standard culture medium.
Coronary artery ligation experimental CHF
All animals in this study received humane care in compliance with the "Principles of Laboratory Animal Care" and the "Guide for the Care and Use of Laboratory Animals." The rat coronary artery ligation model is standard in our laboratory. [28] [29] [30] In brief, SpragueDawley rats were anesthetized with ketamine and acepromazine and underwent a left thoracotomy. The heart was expressed from the thorax and a ligature placed around the proximal left coronary artery.
The rats were maintained post-operatively on standard rat chow, water ad libitum, and pain medication. Only rats with an ejection fraction (EF) of r 35% after permanent left coronary artery ligation at 3 weeks post-MI were enrolled in the study. Three weeks after MI, the chest was reopened, and the NCM-3DFC was implanted with suture on the infarcted ventricle bridging to viable myocardium.
Echocardiography
Closed-chest transthoracic echocardiography was performed using a Vingmed, Vivid 7 system echo machine with EchoPac (both GE Ultrasound, Fairfield, CT) programming software with a 10-MHz multiplane transducer, with views in the parasternal short-axis and long-axis, to evaluate the anterior, lateral, anterolateral, inferior, and posterior walls. Systolic displacement of the anterior wall and EF were obtained from 2D and M-mode measurements of myocardial wall thickness and LV dimensions. 19, 31 Hemodynamic measurements in vivo Rats were anesthetized with a 100 mg/kg intraperitoneal injection of Inactin (Sigma-Aldrich, St. Louis, MO), intubated, and placed on a rodent ventilator with a 2F solid-state micromanometer-tipped catheter with 2 pressure sensors (Millar Instruments Inc, Houston, TX) inserted through the carotid artery. One sensor was located in the LV and another in the ascending aorta. The pressure sensor was equilibrated in 37ºC saline, and LV and aortic pressures/heart rate were recorded and digitized at a rate of 1,000 Hz to calculate LV dP/dt and the time constant (Tau) of LV relaxation. 19, [25] [26] [27] [28] [29] Hemodynamic measurements were obtained at the end of the study, 6 weeks post-MI (3 weeks postimplantation of 3DFC), and 21 weeks post-MI (18 weeks postimplantation).
Statistical analysis
Data are expressed as mean Ϯ standard error (SE)
Results
Cardiomyocyte seeding
Cardiomyocyte seeding densities were evaluated between 0.6 and 2. Figures  1 and 2 , available on the jhltonline.org Web site) with a mean displacement of 1. 
In vitro cellular composition
In vitro quantification of the cellular composition of the NCM-3DFC showed a fibroblast nuclear density (n ¼ 5) of 931 Ϯ 72 and 974 Ϯ 95 nuclei/mm 2 and a cardiomyocyte nuclear density (n ¼
Field stimulation
External field stimulation was applied to the NCM-3DFC at varying culture time points (2-6 days) in temperaturecontrolled (371C) wells. The NCM-3DFC contracted synchronously (Video 2, available on the jhltonline.org Web site) when paced for 20-second intervals at physiologic rates up to 270 Ϯ 30 beats/min. 32 
Cell-to-cell communication
Dye injections into the fibroblasts of the 3DFC alone resulted in no detectable transjunctional diffusion ( Figure 1A ). In contrast, dye diffusion readily occurred from the injected myocytes toward neighboring cells on the NCM-3DFC ( Figure 1B ; Video 3, available on the jhltonline.org Web site). Furthermore, as can be expected from the gradual organization of cell bundles, junctional connectivity increased from Day 2 through 6 days (data not shown). When the NCM-3DFCs were exposed to halothane, dye was retained in the donor cell, reaching higher concentrations but failing to diffuse to the neighboring cells despite the obvious intercellular gradient ( Figure 1C ).
Electrical mapping
The spontaneous electrical activation of the NCM-3DFC was mapped by electrically recording constructs at varying times in tissue culture. The NCM-3DFC yielded maximum and minimum transverse conduction voltage amplitude of 42 mV and -75 mV, respectively. A consistent sequence of transverse activation was seen beat-to-beat (Figure 2 ; Video 4, available on the jhltonline.org Web site).
Hemodynamics and echocardiography
At 3 weeks after implantation, the NCM-3DFC increased (p o 0.05) EF from 31% Ϯ 2% to 39% Ϯ 1% (Figure 3 (Table 2) . Importantly, the rats maintained normal sinus rhythm throughout the entire study, and the echocardiography revealed the previously infarcted area contracted in sync with the rest of the heart, with no arrhythmias and no evidence of dyssynchrony.
LV cross sections
As shown in Figure 4 , implantation of the NCM-3DFC is well tolerated, and within 3 weeks of implantation, the synthetic Vicryl components have degraded and are not visible. As shown by echocardiography and hemodynamic values, implantation of the NCM-3DFC results in improvements of cardiac function. This may be partly due to the effective integration of the transplanted myocytes, or alternatively, enhanced survival/migration/function of endogenous myocardium under the implant. In either case, an increased presence of myocytes in or around the infarcted area was observed (Figure 4) .
Discussion
The present report demonstrates NCMs can be seeded and cocultured onto the 3DFC, resulting in cardiac patches that in vitro contract spontaneously in a rhythmic, synchronous manner in culture (Video 1, available on the jhltonline.org Web site) and are cable of being electrically paced when subject to electrical field stimulation (Video 2, available on the jhltonline.org Web site). We confirmed the existence of functional gap junctions by cell-to-cell diffusion of permeant dye across the patch (Video 3, available on the jhltonline.org Web site; Figure 1B ) and were further validated by transient gap junction inhibition with halo thane, [25] [26] [27] effectively blocking dye passage ( Figure 1C) . Furthermore, electrical mapping of the NCM-3DFC with a multielectrode array system demonstrated consistent beat-tobeat electrical activation and cellular coupling (Video 4, available on the jhltonline.org Web site; Figure 2 ). Quantita tive evaluation of cellular composition showed no loss of cells during tissue culture between 2 and 8 days. These findings support the 3DFC as a suitable construct to support cardiomyocytes and permit structural organization of the Echocardiography evaluation of ejection fraction in rats with chronic heart failure (CHF) at 6, 10, 14, and 18 weeks after patch implantation. Implantation of the neonatal cardiomyocyte (NCM)-3-dimensional fibroblast construct (3DFC) improves ejection fraction at 6 (p ¼ 0.037), 10 (p ¼ 0.015), and 18 (p ¼ 0.046) weeks compared with CHF. Data are mean Ϯ standard error; a (as reported above) and b (p ¼ 0.001 for all groups) denote statistical significance of CHF vs NCMþ3DFC and sham vs CHF respectively. Sham, n ¼ 8 for all groups; CHF, n ¼ 20 at 6 weeks, n ¼ 7 at 10 weeks, n ¼ 6 at 14 weeks, n ¼ 5 at 18 weeks; and NCM-3DFC, n ¼ 26 at 6 weeks, n ¼ 10 at 10 weeks, n ¼ 9 at 14 weeks, n ¼ 5 at 18 weeks. seeded cardiomyocytes in a manner allowing electromechan ical synchrony and thus the potential to track in sinus rhythm in vivo after implantation.
When implanted into rats with CHF and EFs below 35%, the NCM-3DFC improved (p o 0.05) LV function 3 weeks after implantation by increasing EF, cardiac index, dP/dt(þ), dP/dt(-), and PDP, while lowering EDP and LV relaxation (Table 1 ). In addition, long-term improvements were also observed 18 weeks after implantation by increasing EF, MAP, dP/dt(þ), dP/dt(-), and PDP (Table 2 and Figure 3) . Implantations of the NCM-3DFC occurred 18 hours after culture to permit cardiomyocyte adhesion onto the 3DFC yet before the onset of spontaneous contractions and subsequent cellular organization, potentially allowing the underlying native myocardium to dictate organization in vivo. This may have contributed to the observation that all rats that received the NCM-3DFC maintained sinus rhythm with no observed arrhythmias. Echocardiographic data showed no LV dyssynchrony, supporting the observation that the patch does not alter local LV electricalmechanical function (Figure 4) . Furthermore, these findings demonstrate sustained functional improvements, not only over the short-term but long-term.
Although the mechanism of action in cell-based therapies have not been fully elucidated, it should be postulated that many contributory roles are at play that may include transplanted cell survival and paracrine-mediated effects that result in the observed reported functional benefits. Histologic evaluation at 3 and 18 weeks after implantations showed an increase in viable myocardium underneath the patch (Figure 4 ). This population of cells may be in part from the transplanted NCMs, endogenous cardiomyocyte migration, or enhancement of the native viable myocardium. Our previous work has shown that once implanted, the dermal fibroblasts embedded in the 3DFC secrete angiogenic cytokines, establishing microvascular support and increased blood flow.
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The angiogenic cytokines may be supplementing and facilitating the survival of the transplanted cardiomyocytes.
These findings are exciting and support further evaluation of tissue-engineered scaffolds for therapeutic use to treat CHF, but limitations remain that must be overcome. Additional studies will have to be done developing a patch with a clinically relevant cell type. These cells need to be isolated with ease and in robust enough numbers to permit constructing patches. In addition, the concept of allogeneic vs autologous approaches needs to be addressed. In conclusion, this study demonstrates that a multicelluar, electromechanically organized, cardiomyocyte scaffold can be engineered in vitro by seeding and coculturing NCMs onto 3DFC. When implanted in a rat model of CHF, the NCM-3DFC improves short-term and long term LV function when evaluated using echocardiography and hemodynamics.
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Figure 4
Trichrome-stained left ventricular cross sections of (A-C) 6-week chronic heart failure (CHF) control receiving an infarct but no treatment, (D-F) CHF þ neonatal cardiomyocyte (NCM)-3-dimensional fibroblast construct (3DFC) 6 weeks after coronary artery ligation (3 weeks after implant), and (G-I) CHF þ NCM-3DFC 21 weeks after coronary artery ligation (18 weeks after implant). Hearts were excised, and right ventricles were removed and cut in 5-mm transverse sections along the midpoint of the ventricle. Healthy myocardium is represented as red-purple, collagen/scar as blue, and red blood cells as small red dots. The * (A, D, and G) and box insets (B, E, H) represent area of corresponding higher magnification. The þ in panel D and G highlights the location of the NCM-3DFC implant. Implantation of a cardiomyocyte patch results in increased LV wall thickness (D, E, G, H vs A and B) and preservation and/or generation of myocardium (D-F and G-I). The synthetic Vicryl (Ethicon, Somerville, NJ) components of the patch are degradable and not detectable after 3 weeks in vivo. (E and F) Remnants of the suture used for implantation of the NCM-3DFC can be seen as the bright red clusters.
